论文部分内容阅读
目的:分析复合皮移植在治疗功能部位烧伤中的临床效果观察。方法:选取2014年6月至2016年9月广东省中山市阜沙镇阜沙医院收治的60例烧伤创面病患,随机分为两组,对照组给予患者自体刃厚皮片移植修复,观察组给予患者使用复合皮移植修复进行治疗,比较两组病患的全身状况、不良反应、总有效率等。结果:观察组优14例,占46.7%,良15例,占50.0%,差1例,占2.3%,优良率96.7%。对照组优10例,占33.3%,良13例,占43.3%,差7例,占23.3%,优良率为76.7%。观察组优良率高于对照组,差异具有统计学意义(P<0.05);观察组治疗时疼痛评价显著优于对照组,差异具有统计学意义(P<0.05)。观察组面部瘙痒为1例,不良反应发生率为2.3%,对照组4例组织过度增生为4例,面部瘙痒为3例,创面剧烈疼痛为5例,不良反应发生率为33.3%,观察组低于对照组,差异具有统计学意义(P<0.05)。结论:给予病患复合皮移植治疗,治疗效果好,安全有效。
Objective: To analyze the clinical effect of composite skin grafting in the treatment of functional site burn. Methods: Sixty patients with burn wounds treated in Fusha Hospital, Fusha Town, Zhongshan City, Guangdong Province from June 2014 to September 2016 were randomly divided into two groups. Patients in the control group were given self-incised blade skin grafts for repair. Group patients were treated with composite skin graft for treatment, compared the two groups of patients with general condition, adverse reactions, the total effective rate. Results: The observation group was excellent in 14 cases, accounting for 46.7%, good in 15 cases, accounting for 50.0%, poor in 1 case, accounting for 2.3%. The excellent and good rate was 96.7%. The control group was excellent in 10 cases, accounting for 33.3%, good in 13 cases, accounting for 43.3% and poor in 7 cases, accounting for 23.3%. The excellent and good rate was 76.7%. The excellent and good rate of the observation group was higher than that of the control group, the difference was statistically significant (P <0.05). The pain evaluation of the observation group was significantly better than that of the control group, the difference was statistically significant (P <0.05). In the observation group, there was 1 case of itching, 2.3% of adverse reactions, 4 cases of hyperplasia in the control group, 4 cases of facial pruritus, 5 cases of severe wound pain and 33.3% of adverse reactions. The observation group Lower than the control group, the difference was statistically significant (P <0.05). Conclusion: It is safe and effective to treat patients with composite skin grafting.